She holds a Bachelor of Science in Finance degree from Bridgewater State University and helps develop content strategies. In financial markets, the fulcrum point refers to the turning point that ...

He currently spearheads efforts at the technology solutions company Fulcrum to automate manual ... from Duke with a bachelor’s in computer science and joined DoorDash immediately after university.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has a good chance at potentially staging a comeback with its other pipeline drug pociredir, which is being developed in a phase 1b study for the treatment ...

Fulcrum Therapeutics is advancing its lead program, pociredir, with notable progress in the PIONEER trial and plans to release key data from the 12 mg cohort in early Q3 2025. The company’s ...

Losmapimod, a p38 MAPK inhibitor, is a promising drug developed by Fulcrum Therapeutics that is the first compound to target the underlying mechanism of FSHD by inhibiting DUX4. Phase 2 data for ...

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure. The licensing deal with the Big Pharma was agreed ...

Funds went toward developing Fulcrum’s product, hiring staff and moving into a new office space in downtown Minneapolis’ IDS Center. Fulcrum, a Minneapolis-based software-as-a-service firm ...